Soleno Therapeutics Inc SLNO 深 滬
交易中 05-20 09:57:35 美东时间
53.01
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 53.01
- 總市值 27.63亿
- 52周最高 90.3199
- 市盈率 靜 135.61
- 換手率 0.00%
- 52周最低 29.43
- 委 比 0.00%
- 總股本 5212.01万
- 歷史最高 90.3199
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.81
- 每 手 1
- 風險率 16.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Suspends Neutral Rating on Soleno Therapeutics
Cantor Fitzgerald suspends Neutral rating on Soleno Therapeutics (NASDAQ:SLNO).
05-19 20:58
Soleno Therapeutics Completes Merger and Delists from Nasdaq
The latest update is out from Soleno Therapeutics ( ($SLNO) ). On May 18, 2026,...
05-18 21:58
Neurocrine completes Soleno acquisition in USD 2.9 billion deal
Neurocrine completes Soleno acquisition in USD 2.9 billion deal Neurocrine Biosciences completed its acquisition of Soleno Therapeutics in a deal valued at USD 2.9 billion. Soleno shareholders received USD 53 per share in cash. Neurocrine accepted 46,356,114 shares tendered into the offer, represent
05-18 20:47
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong earl...
05-18 20:46
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-09 05:57
财报速睇 | Soleno Therapeutics 2026财年Q1营收0.95亿美元，同比增长100.0%；归母净利润0.31亿美元，扭亏为盈
华盛资讯5月8日讯，Soleno Therapeutics公布2026财年Q1业绩，公司Q1营收0.95亿美元，同比增长100.0%，归母净利润0.31亿美元，扭亏为盈。
05-08 08:02
那些被MNC光速扫货的管线，到底做对了什么？
（来源：商图药讯） 医药行业的并购逻辑正在经历一场结构性的重塑。当2028年的专利悬崖如乌云盖顶般逼近，跨国药企不再迷信那些卷成红海的千亿大靶点...
04-29 19:31
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Wells Fargo Downgrades Soleno Therapeutics to Equal-Weight, Lowers Price Target to $53
Wells Fargo analyst Derek Archila downgrades Soleno Therapeutics (NASDAQ:SLNO) from Overweight to Equal-Weight and lowers the price target from $110 to $53.
04-17 21:03
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Viridian Therapeutics (VRDN) and Soleno Therapeutics (SLNO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
04-11 22:30
